• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Uncategorized

5-FU a promising treatment for CIN-2

bys25qthea
January 4, 2014
in Uncategorized
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/Wiki

1. In this randomized controlled trial, women in the 5-FU group were more likely to have regression of disease and negative HPV status at 6 months. 

2. Women in the 5-FU group reported minimal side effects and high levels of satisfaction with their treatment. 

Evidence Rating Level: 2 (Good)

Study Rundown: This study found that intravaginal 5% 5-fluorouracil (5-FU) is effective in promoting regression of cervical intraepithelial neoplasia-2 (CIN-2) and clearance of HPV. Prior studies have identified topical 5-FU as an effective therapy for preventing recurrence after excisional therapies in HPV-positive women. Current recommendations endorse expectant management of CIN-2, despite the fact that most cases persist or progress to CIN-3. The findings of this study support the use of topical 5-FU as an adjunct, and more proactive option, than watchful waiting of CIN-2.

Results are limited by a small sample size of 56 patients and may be confounded by mandatory dual contraception in the 5-FU group, as condom usage can reduce the risk of infection with different HPV strains. Additionally, actual contraception use was not assessed. Future studies might explore adherence to and efficacy of topical 5-FU treatment in a larger sample to determine whether the results presented here are reproducible.

Click to read the study in AJOG

RELATED REPORTS

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States

Relevant Reading: Management of intravaginal warts in women with 5-FU (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study

Study Author, Dr. Lisa Rahangdale, MD, MPH, talks to 2 Minute Medicine: University of North Carolina, Director, NC Women’s Hospital Dysplasia Clinic, Associate Professor, Department of Obstetrics and Gynecology. 

“Cervical dysplasia management recommendations have changed significantly over the last decade. Physicians are managing a paradigm shift where the expectation is to observe more women, lengthen surveillance windows and treat less. This study submits evidence that a patient-controlled medical option for therapy of cervical disease is desired, effective and safe.”

In-Depth [randomized controlled trial]: This study assessed the efficacy of intravaginal 5% 5-FU (n=31) as compared to observation (n=29), the current standard of care, in treating CIN-2 in women ages 18-29. Outcomes evaluated were regression of disease and HPV status at 6 months, pathology at 12 months, and safety and acceptability of 5-FU treatment.

At 6 months, women treated with 5-FU were more likely to have regression of disease (RR 1.62, CI 1.10-2.56) and clearance of HPV (RR 2.14, CI 1.07-5.37). Among the women evaluated at 12 months, those in the 5-FU group were more likely to have normal colposcopy results (45.0% vs. 25.0%). Overall, 48% of women in the 5-FU group reported side effects such as discharge and irritation but 83% reported satisfaction with treatment.

By Denise Pong, MPH and Leah Hawkins, MD, MPH

More from this author: Repeat third trimester syphilis screening may not be cost effective, Room for improvement in HPV vaccine uptake rates, Educational intervention increases breastfeeding duration in minorities, Pregnancies within 1 year of LEEP more likely to end in spontaneous abortion, Spontaneous early term delivery associated with subsequent preterm birth

©2012-2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Previous Post

Road distractions are significant risk factors for motor vehicle crashes

Next Post

Long-term prophylactic co-trimoxazole beneficial for HIV-positive children in Africa

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
RSV positivity associated with reduced serious bacterial infection risk [Classics Series]
Infectious Disease

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

June 24, 2022
Cardiovascular events in Kawasaki Disease not significantly elevated over controls
Chronic Disease

Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States

June 24, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Gastroenterology Classics

CT evaluation in pancreatitis strongly correlates with patient outcomes [Classics Series]

June 24, 2022
Next Post
HIV-infected infant potentially cured with antiretroviral therapy

Long-term prophylactic co-trimoxazole beneficial for HIV-positive children in Africa

Intake of fish fatty acids associated with lower risk of breast cancer

Triple-negative breast cancer associated with worse survival, similar local recurrence

Different antidepressants associated with similar suicidality risk in children

Different antidepressants associated with similar suicidality risk in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.